Molecule Design

Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represent two fundamentally different search problems. LLM-based molecular design agents typically perform the former, conducting local refinement within the neighborhood of existing structures to improve target properties through structural modifications. In contrast, the latter requires exploration of a broader chemical space to discover molecules with entirely different scaffolds while preserving the functional characteristics of reference molecules. We propose MolHop, an agentic framework for cross-scaffold molecular discovery that enables models to navigate and edit within a pre-organized chemical space. MolHop organizes approximately 1.6 million molecular scaffolds from commercial molecules into a coarse-to-fine hierarchical action space. The agent selects new exploration regions through scaffold navigation actions and adjusts candidate properties through molecular editing. The framework maintains historical trajectory memory to support long-horizon search processes. On drug molecule and commercial compound tasks, connecting Grok-4.6 and DeepSeek-Flash-V4.1 to the MolHop framework substantially improves their cross-scaffold joint success rates. We develop MolHop-9B through agentic reinforcement learning, and MolHop-9B outperforms generative baselines including GPT-5.6-sol, Claude-5-Opus, and Gemini-3.1-Pro, while generating candidate molecules with larger scaffold differences from the reference molecules. These results demonstrate that effective molecular discovery beyond the traditional optimization paradigm requires structured chemical and action spaces, enabling agents to explore new structural regions rather than merely refine existing molecules.

Expected-reward maximization in reinforcement learning concentrates probability mass on a few outcomes, even in tasks that require many distinct, high-quality solutions, a failure known as mode collapse. Inverse Probability Scaling (IPS) counters this in group-based policy gradients such as GRPO by dividing each reward by the outcome's probability, estimated from its frequency within the sampled group. When the outcome space is large relative to the group, outcomes rarely repeat and these estimates become uninformative. Since an outcome can be constructed along many trajectories, its probability is a sum over all of them, and computing it directly is intractable. We propose Marginal IPS (MIPS), which performs marginal evaluation by combining the sampled trajectory with a learned model of the trajectories that lead to each outcome. On Hypergrids, where the exact sampling distribution is computable, MIPS stays near the reward-distribution target as the outcome space grows relative to the rollout group, while frequency-based IPS degrades. In molecular synthesis and phylogenetic inference, MIPS sustains diverse, high-quality sampling where GRPO and frequency-based IPS collapse, showing that MIPS serves as a reliable solution to mode collapse in RL.

Generative discovery in science requires coupling high-level scientific reasoning with the ability to generate samples respecting the structure of a design space. Yet these capabilities remain largely separated: foundation LLMs encode broad chemical and biological knowledge, while domain-specific flow- and diffusion-based generators capture the priors needed to produce valid sequences and geometries. We study how to align such scientific generators to high-level natural-language discovery goals without requiring an explicit proxy reward, which is often unavailable or poorly captured by learned predictors in experimental sciences. We introduce LLM-to-Flow Distillation (LFD), where a frozen LLM acts as an adaptive teacher for a domain-specific generator. Given a goal such as 'generate peptides with promising anticancer activity', the teacher constructs a curriculum of intermediate sub-goals aware of the flow's current capabilities, and progressively directs them toward the original discovery goal. At each round, the LLM judges sampled candidates under the current objective. These judgments induce preferences that are iteratively distilled into the generator through DPO. This procedure provides dense learning signals even when the initial model places negligible probability on designs satisfying the final goal, enabling adaptation toward poorly covered, out-of-distribution regions. Experiments on therapeutic peptides and small-molecule structure design demonstrate that LFD enables a new form of generative control: aligning arbitrary domain-specific scientific generators to scientific discovery tasks expressed via high-level natural-language goals.

Fast, high-fidelity molecular generation requires accurate chemical choices and efficient sampling. Chemical building blocks reduce graph size, but make each node a choice among tens of thousands of related identities. We introduce MIRRA (Molecular Identity Representation, Refresh and Assembly), a discrete flow-matching generator that learns from chemical knowledge and evaluates identity probabilities only when needed, while keeping every identity in its vocabulary available. Chemical features share information across related blocks, and learned identity corrections distinguish them in molecular context. By deciding which positions will refresh before computing their probabilities, the sampler avoids unused predictions while preserving each sampling transition. Against the strongest baselines in each task, MIRRA reduces chemical and graph distribution errors on ZINC250k by 29-31% and 53-60%, respectively, with generation up to 8.6 times faster. Property targeting yields an estimated 7.8-20.8 times more distinct novel hits per second. On a held-out polymer test set, MIRRA achieves 100% periodic validity with known chain topology, versus 57.0% for a polymer variational autoencoder. These results demonstrate fast, high-fidelity generation with the full chemical vocabulary available throughout sampling.

In-silico optimization of nucleic acids relies on predictive oracles that imperfectly capture biological function, so sequences optimized against one model may exploit model-specific artifacts and fail to generalize to independent models. Recent studies have shown that not all designers generalize equally well to independent models. In this work, we use agentic program search to iteratively propose, execute, evaluate, and revise code for nucleic-acid designers. We describe the successful strategies used to prompt the search. AutoNovo designers achieved the best observed mean among the evaluated methods on 3/3 DNA-design tasks in terms of in-silico performance, and 6/6 transfer tasks in terms of independent models. The designers come from a family of discovered nucleic acid designers rather than a single universal best designer. We plan to release the resulting designers. These results are the first steps in creating nucleic acid designers that maximize cross-model generalization, and thus improving the odds that in-silico designed sequences reflect real biology.

Drug discovery requires efficient exploration of an astronomically large chemical space. Molecular graph diffusion models offer a promising approach to this task, but many require graph size to be fixed before generation. Although atom-level insertion and deletion can enable flexible-size generation, jointly modeling molecular size, atom types, and bonds while maintaining chemical validity remains challenging. We introduce FragFlex, a flexible-length discrete diffusion model that performs node insertion and deletion at the fragment level. During denoising, FragFlex jointly learns the size, fragment identities, and inter-fragment connectivity of the fragment graph. A neural attachment-site predictor and valence-aware assembler then convert the generated fragment graph into an atom-level molecule. In large-scale experiments generating 10 million molecules, FragFlex achieves near-perfect chemical validity while maintaining high uniqueness, demonstrating a strong balance between the two.

Machine learning can accelerate molecular discovery by designing molecules and planning experiments. However, many scientific challenges demand molecules with very rare properties, and in this sparse setting, existing algorithms offer little gain over random guessing. We propose a method to efficiently search large regions of molecular space using algorithmically controlled stochastic synthesis. Rather than design, make and test individual molecules, we design and make complex mixtures, test them as a pool, then deconvolute the molecule-activity map. We optimize synthesis to encode maximal information. Theoretically, this approach can reduce the number of experiments required to find the optimal molecule among $d$ candidates from $\mathcal{O}(d)$ to $\mathcal{O}(\log d)$ or $\mathcal{O}(1)$. In simulation, on estimated protein fitness landscapes, it finds active molecules with an order of magnitude fewer experiments than existing Bayesian optimization methods.

Goal-directed molecular design has advanced rapidly, yet a substantial proportion of designed molecules remain difficult to synthesize in practice, limiting their real-world utility. Prior synthesizability-aware methods either project generated molecules back to synthesizable analogs that deviate from the intended target, or optimize directly in discrete synthesis spaces that lack a continuous landscape for efficient search. We argue that this limitation mainly comes from the search space rather than the optimizer. To address this, we propose RouteFlow, a framework that reformulates synthesizable molecular design as a search over a continuous route latent space, where each latent maps back to a complete synthesis route and synthesizability is inherently preserved. To navigate this space, we adopt reward-guided flow matching as an efficient sampler that steers toward high-property regions. Since reward optimization may push latents off the manifold of real synthesis routes, where decoding becomes unreliable, we further introduce a cycle-consistency mechanism to stabilize fine-tuning. Across 16 optimization tasks from Therapeutic Data Commons, RouteFlow achieves the best sample efficiency among synthesizability-aware baselines, with the best synthetic accessibility and the highest retrosynthesis success rate. Our results also confirm that the proposed cycle-consistency reliably keeps optimization on-manifold while improving target properties, supporting effective synthesizable molecular discovery.

Biomolecular therapeutics often start from known sequences and require targeted editing to improve multiple properties while satisfying hard biochemical and manufacturability constraints. However, existing generative methods do not jointly support multi-objective optimization, hard feasibility, and sequence editing in discrete, variable-length biological spaces. In this work, we introduce Pareto-Constrained Molecule Editing (pCoMole), a framework built on discrete flow matching that steers a pre-trained Edit Flow toward user-specified preferences while enforcing terminal feasibility. pCoMole defines a feasibility-gated terminal distribution using an augmented Tchebycheff utility and realizes the resulting preference tilt through a Doob-h transform of the underlying edit process. To make this construction practical, we approximate the required harmonic function using short Monte Carlo rollouts over candidate edits, yielding an efficient guided editor with provable preference consistency. We validate pCoMole by shrinking GFP while retaining fluorescence-related properties, shortening diverse Cas9 orthologs while preserving PAM specificity, and compressing peptide binders into short peptidomimetics that optimize seven drug-related properties under hard constraints. In wet lab testing, two 229-residue pCoMole-designed eGFP variants retained clear green fluorescence in BL21 cells after 10 deletions, with either one or two substitutions. Together, pCoMole enables constraint-aware, Pareto-aligned editing of biomolecular sequences in discrete, variable-length spaces.

Drug design couples property evaluation, conditional generation, structure-based design, and local optimization, yet machine learning systems typically address these capabilities with separate task-specific models. We introduce CAGenMol-2, a masked diffusion molecular language model that represents molecules, continuous scalar properties, and 3D protein pockets within a single wrapped sequence. Within this pretrained interface, downstream operations are selected by which sequence regions are observed or masked at inference, allowing one checkpoint to perform property prediction, property- and pocket-conditioned generation, and partial-constraint design without task-specific architectures or backbone fine-tuning. We further propose Adaptive Fragment Optimization (AdaFO), a gradient-free mask-and-refill search that turns the masked decoder into an iterative local molecular optimizer. On CrossDocked2020, AdaFO increases Success Rate from 30.2% to 70.8%, the best reported under this protocol, while largely preserving drug-likeness and diversity. Finally, scaffold-preserving directional editing and CRBN/VHL case studies demonstrate its use in compound design workflows spanning local molecular editing, structure-based prioritization, and downstream simulation-based screening.

Real-world molecular design remains challenging for large language model (LLM)-based agents. It requires them to interpret design contexts, satisfy multiple constraints, identify infeasible specifications, and reason over multi-step tool outputs. Existing benchmarks do not capture this complexity, focusing instead on explicit and narrow constraints, only feasible problems, and single-path solutions. To address this gap, we propose MolDesignBench, a scenario-grounded benchmark that more closely reflects real-world molecular design for evaluating tool-augmented LLM agents. MolDesignBench comprises 2K generation and optimization instances that combine implicit requirements embedded in design narratives with explicit property and functional-group constraints, including infeasible cases, and require the effective use of 17 specialized chemistry tools. Experiments across diverse frontier LLMs reveal low success rates--with the best achieving only $\sim43$%--and frequent failures in implicit-constraint reasoning, infeasibility detection, and tool reasoning. The corresponding fine-grained failure-mode analysis identifies implicit constraint interpretation and infeasibility detection as the primary bottlenecks, establishing MolDesignBench as a rigorous testbed to guide future research on chemical agents. The benchmark, tool interface, and evaluation code are publicly available.

Molecular design is typically approached as a problem of finding molecules which can adopt a single bioactive conformation. In reality, molecules occupy a distribution over conformations, and many of the properties which determine whether a candidate is viable depend on that distribution rather than on any single conformer. We reframe molecular design as an optimisation of both the modes and properties of molecules' conformational ensembles, where modes can be represented as shapes, pharmacophore profiles or protein pockets, and properties are aggregate scalars computed over the whole distribution. To realise this we introduce ensemble-conditioned guidance, a framework which conditions 3D molecular generative models on both axes simultaneously. Mode conditions are composed adaptively at inference by combining the vector fields produced under each condition. Conditions may be targeted or avoided, mixed across modalities and combined in arbitrary numbers, allowing a wide range of design tasks to be expressed with a single trained model. We introduce adaptive symmetry learning to allow conditions from different reference frames to be composed, and extend our generative framework to enable flexible-size generation. We evaluate on new benchmarks for multi-mode conditioning and ensemble property optimisation, and apply the framework to two practical drug discovery tasks, dual-target binder design and active-state-selective agonist design, where in both cases conditioning on the additional state improves the desired outcome over single-state conditioning.

We introduce Fraglingo, an autoregressive molecular generator that constructs molecules step by step from chemically meaningful fragments connected through predefined attachment sites. At each generation step, Fraglingo jointly predicts which fragment to add and how it should attach by producing an attachment-aware fragment embedding and retrieving the nearest fragment through latent-space search. A wildcard-anchored readout represents both the growing molecule and candidate fragments relative to their attachment sites, enabling a single latent prediction to determine both fragment identity and attachment configuration. Because prediction operates in a continuous embedding space rather than over fixed fragment identifiers, larger fragment libraries can be introduced at inference time without retraining. This retrieval-based formulation provides a unified generation primitive for molecule generation, scaffold generation, scaffold decoration, and molecule optimization. Fraglingo also supports property-conditional generation, allowing desired molecular properties to guide the generation process. On controlled property-conditional benchmarks, Fraglingo achieves stronger joint property control than comparably trained baselines while maintaining competitive validity, uniqueness, and novelty. It also generalizes to fragment libraries up to four times larger than those used during training without retraining. Code is available at: https://anonymous.4open.science/r/FragLingo-3551.

AI-driven de novo molecular design offers a promising route to accelerate early-stage drug discovery by generating novel ligands directly within target protein binding pockets. We present NEAT-POCKET, a pocket-conditioned extension of the autoregressive NEAT model for 3D molecular generation. NEAT-POCKET generates molecules atom by atom in protein pocket environments while preserving atom permutation invariance and explicitly modeling hydrogen atoms. Benchmarks on the CrossDocked and SPINDR datasets show that NEAT-POCKET achieves competitive structure-based generation performance while sampling substantially faster than existing baselines. Beyond full-molecule generation, NEAT-POCKET naturally enables pocket-conditioned fragment completion, a task directly relevant to lead optimization and scaffold elaboration. These results position NEAT-POCKET as a fast, flexible, and practical framework for structure-based drug design.

Designing viable drug candidates requires searching a combinatorially large and rugged chemical space for molecules that satisfy multiple, often competing, objectives. Large language models (LLMs) provide a useful generative prior for this problem because of their representational capacity, reasoning ability, and flexibility when incorporating information from the external environment. While reinforcement learning from verifiable rewards (RLVR) can be used to improve the capabilities of LLMs, many chemically relevant scoring functions require hours or even days per evaluation, making them prohibitively expensive to use directly during online training. Here, we investigate whether LLMs can learn molecular design strategies from cheaper synthetic tasks that generalize to expensive molecular lead optimization settings. We find that curriculum-based training recipes that gradually incorporate more challenging synthetic design tasks enable strong performance that surpasses that of much larger frontier models on structure-based lead optimization. Our results suggest that scaling post-training using synthetic tasks is an effective strategy for adapting LLMs to high-cost experimental scenarios that are too expensive to directly train on.

Improving molecular properties, such as drug-likeness or binding affinity, is a recurring task in early-stage drug discovery. However, molecules optimized in an unconstrained chemical space have limited practical value if they cannot be synthesized. Policy Gradient for Forward Synthesis (PGFS) is a synthesis-aware reinforcement learning method for molecular improvement, but its use of reactant embedding prediction makes reactant selection indirect, which, as we show, limits learning effectiveness. We first develop PGFS+, in which reaction templates and second reactants are represented by trainable embedding lookup tables. Combined with a more effective scoring function and RL algorithm, PGFS+ significantly improves the desired property. However, it exposes a reward-hacking failure mode: a powerful reactant search can map diverse input molecules to the same high-reward magnet molecule, improving the reward while collapsing the output diversity. We therefore introduce PGFS++, a synthesis-aware reinforcement learning framework for input-specific molecular improvement. Given an input molecule, PGFS++ treats it as the start of a forward-synthesis trajectory, applies learned reaction templates with compatible in-stock building blocks, and produces a molecule with improved target properties, an explicit synthesis route, and structural similarity to the input. Experiments on molecular improvement tasks show that PGFS++ improves target properties while preserving high output diversity.

Biomolecular design underpins applications from molecular recognition to therapeutics and synthetic biology, yet de novo interaction design remains challenging-especially for DNA/RNA, underexplored non-protein modalities with scarce, heterogeneous complex data and sharper geometric and chemical constraints. We introduce MCTH (Monte Carlo Tree Hallucination), an inference-only framework that casts all-atom sequence-structure co-design as uncertainty-aware planning over hallucinated states from pretrained folding and inverse-folding models, with optional biophysical control within the same decision loop. MCTH treats these models as frozen black-box operators and uses Monte Carlo Tree Search to allocate a fixed inference budget across competing design trajectories, incorporating model confidence and uncertainty, as well as cross-expert consensus/disagreement when multiple predictors are available. Across protein-RNA, protein-DNA, protein-protein, and protein-ligand design, matched-budget experiments show that adaptive search improves over simpler sampling and cycling strategies, while held-out AlphaFold3 and Chai-1 evaluations demonstrate transfer beyond the search-time oracle. MCTH provides a shared planning layer across modalities while allowing task-specific folding, inverse-folding, and biophysical modules, requiring no fine-tuning or backpropagation through component models.

Early-stage molecular design is an iterative process, not just a task of generating molecules. Researchers turn broad goals into design strategies, refine candidates, assess many properties, and gather evidence before synthesis and tests. AI methods can generate molecules, optimize several goals, predict properties, dock compounds, and account for synthesis. Yet these functions are spread across specialized tools. Experts must still coordinate each step, judge interim results, and integrate evidence. The central challenge is thus to turn research intent into adaptive, traceable runs grounded in scientific tools. We cast this challenge as intent-to-evidence molecular design workflow execution and present CAi Copilot, an expert-oriented agent with three linked layers. The Research Interface Layer turns intent into an executable plan. The Agent Reasoning Layer uses interim results to guide each run. The Execution Substrate supplies molecular tools, metrics, reusable utilities, and backend services. Across 45 tasks, CAi achieves the strongest overall performance, with an outcome score of 84.59, exceeding the next-best result by 18.07 points. Additional benchmarks test how CAi coordinates generation, screening, and multi-criteria evaluation, while exposing limits in long-horizon execution. These results show that CAi turns broad molecular-design intent into transparent, traceable workflows that connect interim decisions to candidate-level evidence.

Most 3D properties relevant to molecular design, including free energies and shape descriptors, are $\textit{expectations}$ over the Boltzmann distribution over 3D configurations of a molecular graph. However, existing property-guided generative models tie each property to a single structure, ignoring the underlying ensemble. We recast 3D molecular design as $\textbf{Boltzmann-expected design}$ and realise it with $\textbf{DECAF}$ (Decoupled Annealing Flows), which factorise the joint distribution over graphs and coordinates into two conditional flow models: a graph-conditioned flow $p(x\mid\mathcal{G})$, acting as a $\textit{Boltzmann emulator}$, and a coordinate-conditioned flow $p(\mathcal{G}\mid x)$, proposing new graphs from 3D information. By alternating the two flows, DECAF optimises molecular graphs with a simulated-annealing acceptance rule whose scoring function is evaluated on ensembles drawn from $p(x\mid\mathcal{G})$, making ensemble statistics, not single-conformer properties, the design target. The resulting loop requires no retraining to change objectives. On GEOM-Drugs, we show that ensemble-aware optimisation produces graphs whose mean radius of gyration and solvent-accessible surface area consistently shift toward targets, while single-conformer optimisation degrades on larger drug-like molecules where Boltzmann distributions are broadest. DECAF extends to multi-objective trade-offs and, uniquely among 3D generative models, to $\textbf{higher-moment design}$: jointly optimising an ensemble property's variance and skewness to produce flexible molecules biased to a prescribed conformational regime: we verify the conformational distributions of these higher-moment designs with all-atom MD simulations.

Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics. Recent breakthroughs in structure prediction, such as AlphaFold-3 and Boltz-2, enable accurate biomolecular interaction prediction and show promise as foundation models for downstream tasks, including binding affinity prediction. We propose to leverage these models and introduce DBMol, a new structure predictor-guided framework for de novo small molecule design. DBMol formulates an alternating optimization and projection process. In the optimization stage, DBMol starts from an initial molecule and uses gradient-based optimization to improve pocket-specific interactions and predicted binding affinity using a structure prediction model. In the projection stage, a flow-matching model maps the optimized molecular graph to discrete and chemically valid molecules. Experiments show that DBMol effectively optimizes the Boltz-2 affinity proxy and generates molecules with strong predicted affinity and specificity under Boltz-2 evaluation. To reduce self-confirmation bias, we further evaluate generated molecules using held-out metrics, including AF3-based evaluation. DBMol substantially improves pocket coverage while maintaining molecular diversity over unconditional generation, and is competitive under held-out metrics despite the absence of reference-ligand supervision. These results support the promise of structure prediction models as effective optimization signals for de novo molecular design.

Generative molecular models can support early drug discovery by proposing new candidate compounds de novo. In practice, useful candidates must balance target-relevant activity, synthetic accessibility, physicochemical properties, and other multiparameter design constraints. However, metrics commonly used to evaluate molecular generators only weakly reflect whether the generated compounds are medicinally plausible and suitable for downstream computation. This can produce false positives in model evaluation, incorrect assumptions, and inefficient use of computational resources. We introduce HEDGEHOG, a unified six-stage filtration benchmark that is inspired by industrial hit identification workflows: (i) preprocessing; (ii) physicochemical descriptor screening; (iii) structural alerts and graph-sanity checks; (iv) synthesis feasibility; (v) docking and binding affinity estimation; and (vi) three-dimensional pose and interaction checks. We evaluate 23 molecular generators across three model classes under a standardized protocol. Across 230,000 generated molecules, only 0.65% of initial molecules survive all stages. Our results expose a central limitation of current molecular generators: molecules that appear acceptable under isolated criteria rarely satisfy medicinal chemistry, synthesis, docking, and 3D pose filters simultaneously.

Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket. However, existing diffusion-based SBDD methods typically couple pocket and ligand representation learning, model interactions only at the atom level, and prioritize binding affinity over other developability properties. Here, we introduce conDitar-dev, a conditional diffusion-based SBDD framework for generating ligands with strong binding affinities and favorable ADMET properties. It consists of three modules: msPRL, a pretrained multi-scale pocket representation learning module; conDitar, a pocket-conditioned diffusion model guided by msPRL representations; and paOPT, a generation-time method for optimizing ligand developability. On a newly curated benchmark of human disease targets, conDitar outperforms state-of-the-art SBDD baselines, achieving an average binding score of -8.85 kcal/mol. Across five ADMET properties, conDitar-dev improves performance by up to 73% over conDitar. To further validate the abilities of conDitar-dev to generate developable molecules, we have applied it to two validated druggable targets: programmed death-ligand 1 (PD-L1) and colony-stimulating factor 1 receptor (CSF1R) proteins. Top-ranked generatively designed molecules and their analogs have been experimentally synthesized and biologically tested. Two molecules generated directly by conDitar-dev for PD-L1 exhibited SPR-derived $K_D$ values of 3.49 and 3.75 $μ$M, respectively. Hit expansion based on conDitar-dev-designed molecules identified selective CSF1R inhibitors with IC$_{50}$ values as low as 200 nM, while also uncovering opportunities for drug repositioning.

Precision molecular design aims to discover personalized drug candidates through joint control of multiple conditions, such as biological relevance and molecular design strategies. Biological relevance reflects cellular functional states under disease or perturbation conditions, while molecular design strategies provide complementary guidance in terms of structural intentions and property optimization. In this study, we propose JoPMol, a jointly controlled precision molecular generative model that integrates biological states encoded by gene expression profiles with molecular structure information expressed in text, and chemical properties quantified by numerical values within a unified modeling framework. This formulation enables coordinated generation and optimization of candidate molecules under joint condition control. Experimental results show that JoPMol outperforms state-of-the-art methods across multiple evaluation metrics. Moreover, JoPMol demonstrates strong generalization ability in both transfer tasks and biologically grounded simulation scenarios, validating its effectiveness for precision molecular design. The source code is publicly available at https://github.com/hala-yh/JoPMol.

The ability to efficiently navigate high-dimensional spaces to identify optimal candidates-whether designing targeted molecular structures or generating images with preferred attributes-stands as a central pillar of modern scientific progress. Recent tree-based samplers enable highly scalable inference-time search by eliminating the reward-gradient bottleneck inherent to particle-based methods. Despite their potential, existing tree-based samplers are fundamentally constrained by the massive number of function evaluations (NFEs) required for node valuation, crippling their utility in exploration-heavy tasks. Furthermore, their reliance on small, uniform transitions at each depth precludes dynamic, adaptive search capabilities. To address this, we introduce Bootstrap Flow-Map-Tree (a.k.a BFMT), a computationally efficient sampling framework that enables full tree-path construction from any tree depth using a single function evaluation, drastically reducing computational overhead while providing critical foresight for sequential sampling. By enabling dynamic transition time-step scheduling, BFMT efficiently allocates its sampling budget, smoothly transitioning from broad global exploration to fine-grained local refinement of high-utility modes discovered through exploration. Extensive experiments and ablation studies across diverse domains-from high-dimensional images to large-scale molecules-demonstrate BFMT's superiority over baseline approaches in both search and alignment tasks.

We present SynLaD, a latent diffusion framework for small-molecule generation that unifies ligand-based drug design objectives (what to make) with synthetic accessibility (how to make it). Current models typically optimize one objective at the expense of the other, creating a bottleneck for discovering high-scoring and synthesizable molecules. SynLaD combines reaction-constrained generation with pharmacophore-conditioned 3D design by learning a latent space that decodes to both 3D structures and synthesis pathways. An encoder maps molecules to a latent representation used by two decoder heads: (i) a geometric head that reconstructs atom types and coordinates and (ii) an autoregressive synthesis head that outputs synthetic routes in a serialized, reaction-based notation. A diffusion transformer generates novel latents in the learned space, conditioned on pharmacophore profiles. Across analogue generation tasks for bioactive ligands, SynLaD outperforms existing baselines in synthesizable and diverse hit generation, demonstrating that a single model can produce shape-aligned molecules with feasible synthesis plans.

Generative molecular models for drug design are a promising direction with much active research. In the next phase of computational drug design, such models will need to understand small molecule structure and protein-ligand interactions, and they will need to possess the machinery to generate molecules de novo. Incorporating each feature poses a critical challenge. Equally important, yet often treated as secondary, is the ability to grow a molecule from a partial starting point -- a scaffold or fragment supplied by a chemist -- which is the central operation of lead optimization. We present Sesame (Spatial Evoformer for a Structure-Aware Molecular Engine), a diffusion-based molecular generation model that leverages a novel spatial pairformer module to condition on partial molecular structure and the surrounding protein pocket, both expressed as continuous spatial density maps. This single conditioning mechanism supports both de novo generation and fragment-conditioned lead optimization, letting a medicinal chemist prune a hit to a scaffold and have Sesame grow it in productive ways. In addition to this module, we also introduce a diffusion framework for joint denoising of atom types, bond types, and positions, along with a trajectory finetuning scheme that trains on the model's own sampling rollouts to improve generation quality. Sesame is trained on a large corpus of ligand-only and protein-ligand datasets.

We present JEDEL, a framework for generating synthesis-ready DNA-encoded libraries (DELs) directly from three-dimensional pharmacophore representations of active ligands. JEDEL is the first model to map pharmacophore interaction patterns to actionable, scalable synthesis instructions, enabling the design of targeted libraries comprising potentially millions of molecules. Unlike existing generative approaches that produce virtual compounds requiring downstream synthesis planning, JEDEL operates within the space of purchasable building blocks and validated reactions, ensuring that every output is experimentally realizable by construction. JEDEL learns a predictive alignment between pharmacophore geometry and molecular structure and decodes this into combinatorial synthesis routes at scale. Across 18 protein targets, it generates focused libraries that outperform random and diversity-based baselines in predicted binding affinity, pharmacophore recovery, and sample efficiency, without target-specific retraining. JEDEL enables a shift from virtual molecule generation to experimentally deployable library design.

Designing molecules with target properties is most useful when candidate structures are accompanied by feasible synthetic routes. We introduce My Chemical Harness, a route-native evolutionary framework for goal-directed molecular design in which the search population consists of executable synthetic pathways rather than isolated molecular graphs. Each route is built from purchasable building blocks and reaction templates, executed by deterministic chemistry tools, and scored through task-specific molecular oracles. Large language models (LLMs) are used only as strategy controllers that select high-level preferences over route length, move type, reaction families, motifs, and exploration pressure, while local code performs route construction, validation, deduplication, scoring, selection, and memory updates. This separation lets the LLM guide exploration without allowing it to introduce hallucinated products or unsupported reaction steps. On a soluble epoxide hydrolase proxy task, our LLM agent improves over single pass LLM and deterministic controllers, reaching state-of-the-art performance across the sEH score, synthetic accessibility score, and AiZynthFinder success rate metrics. These results suggest that constrained LLM agents can play a significant role in molecular discovery without requiring training, fine-tuning, or dedicated generative models.

Can a general-purpose large language model design molecules with the precision of a seasoned chemist? Current LLM-based frameworks answer this question with scalar feedback loops - generate, score, reject - that amount to informed trial-and-error. Here we show that replacing a single number with the full physicochemical rationale from first-principles calculations transforms the LLM from a stochastic sampler into a causal reasoner. Our system couples retrieval-augmented generation with a self-reflection module that feeds orbital energies, atomic charges, and electron densities - rather than compressed scores - back into the design loop. On HOMO-LUMO gap targets from 2.0 to 5.0 eV, this structure-property-relationship (SPR) reflection achieves a deviation as low as 0.0014 eV with a 100% success rate under the SPR+RAG configuration, consistently outperforming scalar-feedback and non-reflective baselines in median and mean deviation. The framework generalizes seamlessly to dipole-moment design, synthetic accessibility optimization, and molecular docking, and proves robust across 7 distinct LLM backbones. These results establish a new paradigm: when the model understands not only that a molecule fails, but why, iterative molecular design becomes genuinely mechanistic.

We present MolLingo, a multi-agent system that emulates the reasoning process of a chemist to automate molecular design. Existing LLM-based approaches either operate as standalone generative models without access to external tools or lack the multi-agent coordination and shared memory needed for iterative, evidence-driven reasoning across the molecular design pipeline. MolLingo addresses this by coordinating a Literature Agent, a Chemist Agent, and an Orchestrator through a shared memory module, with each agent equipped with domain-specific tools. To enable effective molecular reasoning, we introduce BRICS-based Fragment Enumeration (BFE), a synthesis-aware molecular fragmentation method that decomposes molecules into chemically meaningful building blocks represented as block-based SMILES paired with common chemical names. This representation bridges molecular structure and LLM semantic space, enabling block-level reasoning and editing that is difficult with raw SMILES alone. As a case study in early-stage therapeutic design, MolLingo further grounds the Chemist Agent's reasoning in binding site geometry and residue-level protein context derived from molecular docking to optimize molecules for stronger target binding. Across four benchmarks, MolLingo consistently outperforms frontier LLMs and specialized baselines, including a fourfold docking score improvement over GPT-5.4 despite using the same underlying model, consistent drug property optimization gains across multiple LLM backbones, and state-of-the-art results on TOMG-Bench, surpassing both frontier LLMs and the RL-based optimization method RePO. Our results suggest that LLMs are already capable molecular design assistants when guided through chemically meaningful representations and biologically grounded structural context. Code is available at: https://anonymous.4open.science/status/MolLingo-7450.